IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases
“Despite the current treatments and recent gene therapies, we believe that there remains a pressing need for globally accessible, effective, and convenient oral therapies for people with SCD," said Anil Goyal, Ph.D., CEO and co-founder of IMMvention.